Stockreport

AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure [Yahoo! Finance]

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms Initial results are expected in [Read more]